Navigation Links
Bavarian Nordic Publishes its Annual Results 2008
Date:3/27/2009

KVISTGAARD, Denmark, March 27 /PRNewswire-FirstCall/ -- Today Bavarian Nordic published the company's Annual Report 2008. The report is available on the company's website: http://www.bavarian-nordid.com.

Bavarian Nordic's revenue for the year 2008 was DKK 209 million with a loss before tax of DKK 183 million, which was in line with the Company's latest guidance. At year-end 2008, net free cash and cash equivalents stood at DKK 796 million. For 2009, Bavarian Nordic expects revenue in the region of DKK 375 million, and a pre-tax loss in the region of DKK 225 million. Revenue will primarily be generated from the delivery of IMVAMUNE(R) to the United States under the RFP-3 contract and billing of the continuation of the RFP-2 contract and contracts for smallpox vaccines already entered with other countries.

For 2009, the Company will make extraordinarily large drawings on cash as a result of increased costs for scaling up production, the continuing build-up of stockpiles of vaccine, preparation of the Phase III study of PROSTVAC(TM) and increased costs of Phase II and the preparation of Phase III studies of IMVAMUNE(R). It is expected that drawings on cash in the current year will be at the level of DKK 400 million. Accordingly, the Company's net free liquidity is expected to be at the level of DKK 400 million at the end of the year. The expectations regarding the liquidity are based on a dollar exchange rate of approx. 6 DKK/USD. Bavarian Nordic expects to strengthen its net free liquidity in 2010 and in the years ahead via the delivery of already entered IMVAMUNE(R) contracts. Thus, at the end of 2012, Bavarian Nordic's net free liquidity is expected to be in level with 2008.

    2008 highlights

    - Strong progress in the pipeline with two new programmes added and two
      other programmes entered clinical trials:

    - PROSTVAC
'/>"/>
SOURCE Bavarian Nordic A/S
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Bavarian Nordic Receives $50 Million Advance Payment from HHS for Fulfilling Contract Milestones
2. Bavarian Nordic Update - 2007 Annual Results, IMVAMUNE(R) Delivery Contract, Strategy Process
3. Bavarian Nordic A/S - Interim Report for the Period 1 January to 30 June 2008
4. Bavarian Nordic Receives USD 25 Million Milestone Payment After Submission of Important IMVAMUNE(R) Data to The U.S. Health Authorities
5. Bavarian Nordics Case Against Oxford BioMedica
6. Bavarian Nordic Has Essentially Agreed a Pathway for the Licensure of IMVAMUNE(R) With the FDA After Successful End of Phase II Meeting
7. Circulation Publishes MERLIN TIMI-36 Data Showing Safety and Anti-Arrhythmic Effects of Ranexa(R)
8. Thomson Scientific Publishes Who Is Making The Biggest Splash? - A Quarterly Review of Scientific Literature on Drugs and Therapies From April - June 2007
9. Consortium publishes Phase II map of human genetic variation
10. The Lancet Publishes Vasogens ACCLAIM Results
11. Dendreon Publishes Manuscript on CD54 as a Surrogate Marker of Antigen Presenting Cell Activation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2014)... , Nov. 24, 2014  IGI Laboratories, Inc. ... based specialty generic pharmaceutical company, today announced it ... to the U.S. Food and Drug Administration (FDA), which ... 2014 to seven, with eighteen submissions now pending at ... President and CEO of the Company, commented, "Our team ...
(Date:11/24/2014)... SOUTH SAN FRANCISCO, Calif. , Nov. 24, 2014 /PRNewswire/ ... announced that Bonnie H. Anderson , president and chief ... the Piper Jaffray 26 th Annual Healthcare Conference on ... New York . The live audio ... website at http://investor.veracyte.com . Please connect to the website ...
(Date:11/24/2014)... 2014  Spherix Incorporated (Nasdaq: SPEX ... fostering and monetization of intellectual property, today provided ...  Case No. 3:13-cv-03494-M and  Spherix v. Uniden Corporation ... the United States District Court for the Northern ... On November 21, 2014 the Markman ...
(Date:11/22/2014)... Prominent academics, leaders of the ... December 3rd at Genetic Rx, a networking conference ... take place at the Joseph B. Martin Conference ... the present and future of genetic medicines—including siRNA, ... editing—as well as the treatment of patients with ...
Breaking Biology Technology:IGI Laboratories, Inc. Announces ANDA Submission 2Veracyte to Present at the Piper Jaffray 26th Annual Healthcare Conference 2Markman Hearing Held as Scheduled in VTech and Uniden Cases 2Pioneering Academics and Key Industry Leaders to Discuss Rare Diseases and the Emergence of New Genetic Medicines at Genetic Rx on December 3rd 2
... May 5 Silence Therapeutics plc (AIM: ... Jorg Kaufmann , Ph.D., to the position of ... Kaufmann, who previously served as senior director, technologies at ... Company,s broad range of RNA interference (RNAi) research activities, ...
... Healthcare ... Finance and Administration. Mr. Wilson brings over 25 years experience in this field and ... ... Mitchell Wilson has joined the company as Vice President of Finance and Administration. Mr. ...
... Inc. (Nasdaq: ITMN ) today announced that the U.S. Food and ... Application (NDA) for Esbriet™ (pirfenidone) for the treatment of patients with idiopathic ... , , ... the FDA,s Center for Drug Evaluation and Research when the review of ...
Cached Biology Technology:Silence Therapeutics Appoints New Vice President of Research 2Silence Therapeutics Appoints New Vice President of Research 3Healthcare Data Solutions Announces New Executive Team Member 2InterMune Receives FDA Complete Response Letter on Esbriet(TM) (Pirfenidone) New Drug Application 2InterMune Receives FDA Complete Response Letter on Esbriet(TM) (Pirfenidone) New Drug Application 3InterMune Receives FDA Complete Response Letter on Esbriet(TM) (Pirfenidone) New Drug Application 4InterMune Receives FDA Complete Response Letter on Esbriet(TM) (Pirfenidone) New Drug Application 5
(Date:11/4/2014)... death at the right time might actually help boost ... could help in understanding animal populations, pest control and ... in the journal Trends in Ecology and Evolution ... that the kind of positive population effect an overall ... depends on the size and developmental stage of the ...
(Date:11/4/2014)... 4, 2014) — Think about the way our bodies ... neighboring cells know that they are supposed to become ... these tissues find the correct place and alignment? Researchers ... crucial questions. , In a new study, UM researchers ... with their surrounding neighbors, at the head-trunk region. Their ...
(Date:11/4/2014)... OXFORD, England , November 4, 2014 ... expansion and vertical market growth   Fuel3D ... it has closed a funding round totaling $6.4 million (£4 ... (£1.6 million) funding secured earlier this year and paves the ... product in 2015. The funding round was led ...
Breaking Biology News(10 mins):When less is more: Death in moderation boosts population density in nature 2The inside story: How the brain and skull stay together 2Fuel3D Secures $6.4 Million in Expansion Funding 2Fuel3D Secures $6.4 Million in Expansion Funding 3
... article by Stevens Institute of Technology researchers featured as ... Volume 98, Issue 7 represents a step forward in ... Dr. Chang-Hwan Choi and Dr. Eui-Hyeok (EH) Yang, and ... focuses on nanowires, structures that are mere nanometers in ...
... Ga., Feb. 23, 2011 MiMedx Group, Inc. (OTC ... manufacturer and marketer of patent protected biomaterial-based products, announced ... full year ended December 31, 2010, and Company guidance ... on Monday, March 28, 2011.  The timing of the ...
... awarded a prestigious Sloan Research Fellowship. Chen, a Canada ... subject: deciphering the assembly instructions for the brain. ... with precision. One of the central puzzles in neuroscience ... during its development when faced with thousands of potential ...
Cached Biology News:Nanowire research at Stevens makes cover of Applied Physics Letters 2MiMedx Group, Inc. Announces Release Date for 2010 Fourth Quarter and Full Year Results 2Prestigious Sloan Fellowship awarded 2
... Instech Solomon's laboratory animal infusion kits reduce ... an infusion study while providing sterile equipment ... kit includes everything you need for one ... Tubing and tethers will be cut to ...
... Plus is a small and ... market for both LC and IC. It ... Atmospheric Pressure Ionization (API) source for outstanding ... is compatible with existing LC and IC ...
Kit for BASE20/50 dual control unit, includes mounting plate, HOLDER50T, HEATERPAD50, SRTDX temperature probe(s)....
...
Biology Products: